XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.1

Note 4 - Trade Receivables

3 Months Ended

Mar. 31, 2022

Notes to Financial Statements

Trade Receivables [Text Block]

Note 4 — Trade Receivables

Product Sales

Receivables from product sales are recorded for amounts due to the Company related to sales of ORLADEYO and RAPIVAB. At March 31, 2022 and December 31, 2021, receivables related to sales of ORLADEYO were $34,405 and $27,384, respectively. At March 31, 2022 and December 31, 2021, receivables related to sales of RAPIVAB were $78 and $49, respectively. No reserve or allowance amounts were recorded as of March 31, 2022 and December 31, 2021, respectively.

Collaborations

At March 31, 2022 and December 31, 2021, the Company had the following receivables from collaborations:

		March 31, 2022
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	5			$	1,600			$	1,605
Royalty receivables from partners			327				—				327
Total receivables		$	332			$	1,600			$	1,932

		December 31, 2021
		Billed				Unbilled				Total
U.S. Department of Health and Human Services		$	5			$	1,670			$	1,675
Royalty receivables from partners			305				—				305
Total receivables		$	310			$	1,670			$	1,980

As of both  March 31, 2022 and December 31, 2021, the Company maintained a reserve of $701 related to royalties associated with Green Cross. 

X

- Definition

The entire disclosure for trade receivables.

+ References

No definition available.

+ Details

Name:	bcrx_TradeReceivablesTextBlock
Namespace Prefix:	bcrx_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_DisclosureTextBlockAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration